Triastek

Triastek (三迭纪, full name "南京三迭纪医药科技有限公司") is a Nanjing-based 3D-printed drug technology platform founded in 2015 . The company developed MED® (Melt Extrusion Deposition), a proprietary 3D printing process for solid-dose pharmaceuticals that enables programmable control over drug release timing, location, and rate through internal three-dimensional structures . As of September 2023, Triastek held over 200 patents—roughly 20% of all applications in the global 3D-printed drug field—and had three products with four IND approvals across China and the US, making it the only Chinese pharmaceutical company selected for the FDA's Emerging Technology Program . Its commercial partnerships include Eli Lilly, Boehringer Ingelheim, Merck, Siemens, and BioNTech, with the latter representing a technology platform licensing deal valued at over $1.2 billion announced in July 2024 . Yunqi Capital led Triastek's A+ round and has continued to back the company through its Pre-C round of RMB 150 million in September 2023 .